PknG Inhibitor is a cell-permeable tetrahydrobenzothiophene compound that acts as a highly specific and ATP-binding site-targeting inhibitor against mycobacterial protein kinase G (PknG; IC50 = 390 nM), while exhibiting much reduced or no activity against 8 other mycobacterial and 25 other human kinases, including PKCα, the mammalian kinase most closely related to PknG. AX20017 is shown to completely inactivate PknG-mediated blockage of lysosomal transfer and degradation of M. bovis BCG in macrophages at concentrations (10μM or higher) that does not otherwise affect the growth of BCG outside its infected host.
1. Walburger, Anne., et al., 2004. Protein kinase G from pathogenic mycobacteria promotes survival within macrophages. Science (New York, N.Y.). 304(5678): 1800-4. PMID: 15155913
See how others have used PknG Inhibitor (CAS 329221-38-7). Click on the entry to view the PubMed entry .
PMID: # 28237032 Chen, D. et al. 2017. Tuberculosis (Edinb). 103: 37-43.
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.